MTOR and glioblastoma: Furthermore, paxalisib, a small molecule capable of penetrating the blood–brain barrier and inhibiting the PI3K/AKT/mTOR pathway, has demonstrated clinical activity in newly diagnosed GBM patients with unmethylated MGMT promoters (56).